Repligen Completes Expansion of U.S. Manufacturing Facility
News Nov 07, 2013
Repligen Corporation has announced that it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met.
A dedicated production suite more than doubles capacity for the Company's OPUS® line of pre-packed chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment to satisfy the Good Manufacturing Practices (GMP) standards of the Company's biopharmaceutical customers.
"This expansion will enable us to meet the critical needs of our customers for quality and timely delivery," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen.
Herlihy continued, "The new cleanroom suite enables us to produce OPUS® columns under the highest quality standard demanded by biopharmaceutical manufacturers."
The facility expansion also triples warehouse space and includes dedicated purification and fermentation laboratories for optimization of existing manufacturing processes, new product development and applications support.
An additional 17,000 square feet is reserved for future expansion of the same facility, allowing the Company to remain flexible and responsive to the needs of its biopharmaceutical customers and life sciences partners.
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018